JAX Home

Edison T. Liu, M.D.

President, CEO

Conducts research focused on the functional genomics of breast cancer through an exploration of the entire genomic space.

The JAX Cancer Center

Visit The Liu Lab

About Edison T. Liu, M.D.

Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001-2011), and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he was in charge of the intramural clinical translational science programs.

From 1987 to 1996, Dr. Liu was a faculty member at the University of North Carolina at Chapel Hill, where he was the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer; the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health; chief of Medical Genetics; and the chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology and translational medicine.

Dr. Liu's own scientific research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering on a genomic scale the dynamics of gene regulation that modulate cancer biology. He has authored over 300 scientific papers and reviews, and co-authored two books. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, at the G.W. Hooper Foundation.

Grants, honors and accomplishments

2014 April - 2014 Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research (from the Human Genome Organization)

2013 January - Elected, Fellow of the Connecticut Academy of Sciences and Engineering

2010 October - Fellow of the Hastings Center (New York, Elected Membership)

2010-2013 - Re-elected - President, Human Genome Organization (HUGO)

2008 - Elected, Foreign Associate Member, European Molecular Biology Organization (EMBO)

July 2007 - Awarded Doctor of Medical Sciences honoris causa, Queen’s University, Belfast September

June 2007-2010 - Elected – President, Human Genome Organization (HUGO)

September 2003 - Public Service Medal (National Day, 2003): for work in controlling SARS in Singapore (given by the Office of the President, Republic of Singapore)

April 2000 - Rosenthal Award, AACR: for the discovery that HER-2 status determines response to adjuvant chemotherapy with doxorubicin.

April 1999-2001 - Elected-Board of Directors, American Association for Cancer Research

October 1996 - 1996 Brinker International Award for Breast Cancer Research - Basic Research Award

July 1995 - American Society of Clinical Investigation (Elected Membership)

December 1991-November1996 - Leukemia Society Scholar

October 1990-1993 - Komen Foundation Award for Breast Cancer Research (funding fellow salary)

July 1990-June 1994 - Jefferson Pilot Award: University of North Carolina at Chapel Hill, Junior Faculty Award for Research Excellence

July 1985-1988 - Clinical Investigator Award, National Cancer Institute, K08- CA01036-02, Preceptor: Dr. J. Michael Bishop.

September 1983-1985 - Damon Runyan Cancer Fund Fellowship Preceptor: Dr. J. Michael Bishop (UCSF)

July-September 1974 - Ford Foundation Fellowship for Intensive Studies in Chinese, Stanford University

June 1973 - Phi Beta Kappa, Stanford University

June-September 1972 - National Science Foundation Fellowship in Chemistry 1972. To study the photoconversion of aziridines to ethylene for its agriculture applications. Preceptor: Dr. J. D. White

Selected Publications

Highlighted Abstract

Next-generation sequencing studies have revealed genome-wide structural variation patterns in cancer, such as chromothripsis and chromoplexy, that do not engage a single discernable driver mutation, and whose clinical relevance is unclear. We devised a robust genomic metric able to identify cancers with a chromotype called tandem duplicator phenotype (TDP) characterized by frequent and distributed tandem duplications (TDs). Enriched only in triple-negative breast cancer (TNBC) and in ovarian, endometrial, and liver cancers, TDP tumors conjointly exhibit tumor protein p53 (TP53) mutations, disruption of breast cancer 1 (BRCA1), and increased expression of DNA replication genes pointing at rereplication in a defective checkpoint environment as a plausible causal mechanism. The resultant TDs in TDP augment global oncogene expression and disrupt tumor suppressor genes. Importantly, the TDP strongly correlates with cisplatin sensitivity in both TNBC cell lines and primary patient-derived xenografts. We conclude that the TDP is a common cancer chromotype that coordinately alters oncogene/tumor suppressor expression with potential as a marker for chemotherapeutic response.

Featured ArticleJune 03, 2020
Science for the common good: a discussion on Covid 19
In their first Jaxtaposition virtual event, leaders from the Jackson Laboratory discussed COVID-19-related research, the origins of the virus, its clinical impacts, and how we can target therapeutics.
- Infectious Disease
- Infectious Disease Research
Blog PostMay 04, 2020
Updates in BRCA testing for People of Ashkenazi Jewish Ancestry
The traditional approach to genetic testing for those of Ashkenazi Jewish ancestry is under debate, with some experts calling for testing all Ashkenazi Jewish individuals and others advocating for further research to inform any changes in testing criteria.
Research HighlightApril 13, 2020
Aggregating genomic data to improve precision oncology
Using a new meta-knowledgebase, cancer researchers have demonstrated improved matching between a patient cohort and variant interpretations of potential clinical significance, from an average of 33% per individual knowledgebase to 57% in aggregate.
- Cancer/Tumors
- Cancer
Featured ArticleApril 05, 2020
The new normal after the COVID-19 surge
Now that we have social distancing policies and protocols in place, how long will it be before they can be relaxed?

Press ReleaseMay 13, 2020
National Cancer Institute Renews Jackson Laboratory’s Cancer Center Designation
JAX's Cancer Center designation has been renewed for the 34th year by the National Cancer Institute.
Featured ArticleApril 16, 2020
Q&A: Modernizing genomics education
Meet Janet Belval, a South Windsor, Connecticut science teacher.
Search MagazineApril 08, 2020
Cutting off cancer's fuel supply
Computational scientists are on the front lines in the cancer fight.
Search MagazineApril 01, 2020
Cancer: Does it run in the family?
Helping clinicians take better family histories improves patient cancer risk assessments.

Edison T. Liu, M.D.

President, CEO

About Edison T. Liu, M.D.

Selected Publications

Highlighted Abstract

Essential

Analytics

Marketing